The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
Open accessAbstract
BACKGROUND: Losartan is a new specific angiotensin II receptor antagonist with no agonist properties that provides the opportunity to study the consequences of angiotensin II blockade. The objective of the present study was to evaluate the hemodynamic and neurohormonal response to losartan in patients with congestive heart failure. METHODS AND RESULTS: After baseline hemodynamic measurements using balloon-tipped pulmonary artery and radial arterial catheters, patients were randomized to receive a single dose of placebo or 5, 10, 25, 75, or 150 mg losartan in a double-blind, sequential fashion. Hemodynamic and neurohormonal parameters were then measured periodically for 24 hours. Losartan caused vasodilation in a dose-dependent manner. By the area-under-the-curve method, the reduction in the mean arterial pressure and systemic vascular resistance grew larger up to a dose of 25 mg, but the higher 75- and 150-mg doses did not produce additional vasodilation. In response to losartan, there were compensatory increases in both angiotensin II concentrations and in plasma renin activity, which were greatest at the highest doses. Aldosterone concentrations were significantly lowered with losartan. CONCLUSIONS: Blockade of the angiotensin II receptor with the antagonist losartan causes vasodilator and neurohormonal effects in patients with congestive heart failure. The lack of additional vasodilator response with doses of more than 25 mg suggests that neurohormonal activation might limit the efficacy of high dose of losartan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonpeptide angiotensin II receptor antagonists
Timmermans, P. B. M. W. M., Wong, P. C., Chiu, A. T., & Herblin, W. F. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90498-h · Cited by 549
Wong, P. C., Price, W. A., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., & Timmermans, P. B. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)19984-9 · Cited by 269
Levine, T. B., Franciosa, J. A., & Cohn, J. N. (1980) · Circulation · doi:10.1161/01.cir.62.1.35 · Cited by 257
Self-citationAngiotensin converting enzyme inhibition in patients with congestive heart failure.
Gavras, H., Faxon, D. P., Berkoben, J., Brunner, H. R., & Ryan, T. J. (1978) · Circulation · doi:10.1161/01.cir.58.5.770 · Cited by 244
Determinants of angiotensin II generation during converting enzyme inhibition.
Juillerat, L., Nussberger, J., Ménard, J., Mooser, V, Christen, Y., Waeber, B., Graf, P., & Brunner, H. R. (1990) · Hypertension · doi:10.1161/01.hyp.16.5.564 · Cited by 212
The Broad Substrate Specificity of Human Angiotensin I Converting Enzyme
Skidgel, R. A., & Erdös, E. G. (1987) · Clinical and Experimental Hypertension. Part A: Theory and Practice · doi:10.3109/10641968709164184 · Cited by 161
Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma.
Nussberger, J., Brunner, D. B., Waeber, B., et al. (1986) · Hypertension · doi:10.1161/01.hyp.8.6.476 · Cited by 131
Fenoy, F. J., Scicli, G. M., Carretero, O. A., & Roman, R. J. (1991) · Hypertension · doi:10.1161/01.hyp.17.6.1038 · Cited by 88
Hirsch, A. T., Talsness, C. E., Smith, A. D., Schunkert, H., Ingelfinger, J. R., & Dzau, V. J. (1992) · Circulation · doi:10.1161/01.cir.86.5.1566 · Cited by 69
Kinin contribution to renal vasodilator effect of captopril in rabbit.
Hajj-Ali, A. F., & Zimmerman, B. G. (1991) · Hypertension · doi:10.1161/01.hyp.17.4.504 · Cited by 57
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Self-citationPitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDATE THE 2005 GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILURE WRITING ON BEHALF OF THE 2005 HEART FAILURE WRITING COMMITTEE, Jessup, M., Abraham, W. T., Casey, D. E., Feldman, A. M., Francis, G. S., Ganiats, T. G., Konstam, M. A., Mancini, D. M., Rahko, P. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192064 · Cited by 1,419
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Dickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Self-citationAngiotensin II receptor antagonists
Burnier, M., & Brunner, H. (2000) · The Lancet · doi:10.1016/s0140-6736(99)10365-9 · Cited by 707
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Konstam, M. A., Neaton, J. D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F. A., Riegger, G. A., Malbecq, W., Smith, R. D., Guptha, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61913-9 · Cited by 646
Self-citationLiu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Angiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 473
Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Horiuchi, M., Akishita, M., & Dzau, V. J. (1999) · Hypertension · doi:10.1161/01.hyp.33.2.613 · Cited by 473
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167587 · Cited by 464
Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation
Nakashima, H., Kumagai, K., Urata, H., Gondo, N., Ideishi, M., & Arakawa, K. (2000) · Circulation · doi:10.1161/01.cir.101.22.2612 · Cited by 443
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.023 · Cited by 309
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler, M., & Esler, D. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002450 · Cited by 296
Losartan in Heart Failure: Hemodynamic Effects and Tolerability
Crozier, I., Ikram, H., Awan, N., Cleland, J., Stephen, N., Dickstein, K., Frey, M., Young, J., Klinger, G., Makris, L., et al. (1995) · Circulation · doi:10.1161/01.cir.91.3.691 · Cited by 291
Self-citation2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.020 · Cited by 288
ACE2 of the heart: From angiotensin I to angiotensin (1–7)
KEIDAR, S., KAPLAN, M., & GAMLIELLAZAROVICH, A. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.006 · Cited by 278
Metadata
- Authors
- Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., & DeKock, M.
- Venue
- Circulation
- Published
- 1993-10
- Volume
- 88
- Issue
- 4
- Pages
- 1602-1609
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2051868585
- Cited by
- 291
- References
- 10
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.